Brentuximab vedotin and anti-PD1 treatment optimize survival in chemo-refractory Hodgkin lymphoma patients: Real-world data.
Sakellari I, Gavriilaki E, Iskas M, Bousiou Z, Chatziioannidis A, Batsis I, Mallouri D, Constantinous V, Stavroyianni N, Syrigou A, Marvaki A, Pilavaki M, Papaemmanouel S, Anagnostopoulos A.
Sakellari I, et al. Among authors: mallouri d.
Hematol Oncol. 2019 Oct;37(4):490-492. doi: 10.1002/hon.2645. Epub 2019 Jul 24.
Hematol Oncol. 2019.
PMID: 31339579
Clinical Trial.
No abstract available.